IP Library Granted Patent US 6,933,291
Granted Patent B2
US 6,933,291 · App. 09/726,308 · Granted Aug 23, 2005

Cholesterol lowering supplement

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,933,291
App. No.
09/726,308
Granted
Aug 23, 2005
Kind
B2
Abstract

The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as suitable composition comprising (a) one or more phytosterols and/orphytostanols or a mixture thereof capable of reducing cholesterol absorption in the intestine, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions b. and c. is preferably derived from plants.

Claims (30)

1. A composition comprising:

a. one or more phytosterols and/or phytostanols or a mixture thereof capable of reducing cholesterol absorption in the intestine;

b. a composition capable of inhibiting cholesterol biosynthesis;

c. a composition capable of increasing cholesterol metabolism,

wherein at least one of compositions b. and c. is derived from plants.

2. A composition according to claim 1 , wherein the at least one of compositions b. and c. is an extract from a plant or plant parts.

3. A composition according to claim 2 , wherein compositions b. and c. are extracts from different plants or parts thereof.

4. A composition according to claim 1 , wherein composition b. capable of inhibiting cholesterol biosynthesis comprises one or more HMG-CoA reductase inhibitors and/or squalene synthase inhibitors.

5. A composition according to claim 4 , wherein the composition capable of inhibiting cholesterol biosynthesis comprises one or more NMG-CoA reductase inhibitors.

6. A composition according to claim 4 , wherein the composition capable of inhibiting cholesterol biosynthesis is derived from a plant or plant part selected from the group consisting of Alisma orientale, Typha spp., Salvia miltiorhiza, Polygonum multiflorum, Curcuma spp., Ligusticum spp., Polygonun spp., Polygonun cuspidatum; Corydalis spp; Chrysanthemum morifolium; Arthemisia capillaris; Crataegus pinnatifida, Eleutheroccus senticocus, Astragalus membranaceus and subspecies or varieties thereof.

7. A composition according to claim 6 , wherein the composition capable of inhibiting cholesterol biosynthesis is an aqueous extract of Polygonum multiflorum.

8. A composition according to claim 1 , wherein composition a. contains at least 25% by weight of phytosterols and/or phytostanols.

9. A composition according to claim 1 , wherein the phytosterol and/or phytostanol or mixture thereof comprises a plant sterol obtained from vegetable oil or wood pulp.

10. A composition according to claim 9 , comprising a phytosterol selected from the group consisting of sitosterol, stigmasterol, ergosterol, campesterol, avenasterol, brassicasterol, desmosterol, chalinosterol, poriferasterol, clionasterol, sitostanol, stigmastanol and campestanol.

11. A composition according to claim 1 , wherein composition c. capable of increasing cholesterol metabolism comprises an effective amount of a composition capable of increasing conversion of cholesterol into bile acids and/or inhibiting the esterification of cholesterol.

12. A composition according to claim 11 , wherein composition c. comprises one or more cholesterol 7a-hydroxylase activators and/or one or more Acyl-CoA acyl transferase inhibitors.

13. A composition according to claim 12 , wherein the composition capable of increasing cholesterol metabolism is derived from a plant or plant part selected from the group consisting of Polygonum multiflorum, Polygonum cuspidatum, Curcuma spp., Ligusticum spp., Polygonatum spp., Corydalis spp., Chrysanthemum morifolium, Arthemisia capillaris and Acanthopanax senticosus.

14. A composition according to claim 13 , wherein the composition comprising an effective amount of a composition capable of increasing cholesterol metabolism is an aqueous extract of Chrysanthemum morifolium.

15. A food or beverage product comprising a composition according to claim 1 .

16. A nutritional supplement comprising a composition according to claim 1 .

17. A tablet, capsule, microbead, emulsion, powder, granule, suspension, syrup, elixir or chewing gum comprising a composition according to claim 1 .

18. A composition according to claim 1 , further comprising a component selected from the group consisting of poly-unsaturated fatty acids, antioxidants, phospholipids, folic acid, vitamin B12, vitamin B6, magnesium, coenzyme Q10 and zinc.

19. A composition according to claim 18 , wherein the polyunsaturated fatty acids comprise omega-6-fatty acids and/or omega-3-fatty acids.

20. A composition according to claim 18 , wherein the phospholipids comprise lecithin.

21. A composition according to claim 18 , wherein the antioxidants comprise tocopherols.

22. A composition according to claim 21 , wherein the tocopherols comprise vitamin E.

23. A method of reducing serum cholesterol levels or inhibiting elevated blood serum cholesterol levels comprising administering to a person in need thereof an effective amount of a composition comprising:

a. one or more phytosterols and/or phytostanols or a mixture thereof capable of reducing cholesterol absorption in the intestine;

b. a plant-derived composition capable of inhibiting cholesterol biosynthesis; and

c. a plant-derived composition capable of increasing cholesterol metabolism.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: PHARMACHEM LABORATORIES, INC.
To: UNICITY PROPERTIES,INC.
Reel/Frame 034385/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2014
From: FORBES MEDI-TECH INC.
To: PHARMACHEM LABORATORIES, INC.
Reel/Frame 032174/0076 →
RELEASE OF SECURITY INTEREST Recorded Mar 4, 2011
From: JPMORGAN CHASE BANK, N.A.
To: GENERAL NUTRITION INVESTMENT COMPANY
Reel/Frame 025905/0054 →